DNA methylation alterations as therapeutic prospects in thyroid cancer
- 177 Downloads
Thyroid cancer is one of the most common endocrine malignancies. Although the 10-year survival rate of differentiated thyroid cancer (DTC) is about 90% after conventional treatments, a small proportion of patients still suffer from tumor recurrence or drug resistance.
This review article summarizes recent researches and clinical trials related to target drugs that reduce mortality in thyroid cancer.
This is a review of the recent literature and clinical trials on the three main aspects including methylation genes in thyroid cancers, the relationship between BRAF mutation and gene methylation, target and dehypermethylation drugs in clinical trials.
We propose new approaches to treating malignant thyroid cancer, based on advances in understanding the relationship between genetic and epigenetic changes in thyroid cancer. Although the effect of traditional treatment for thyroid cancer is relatively good, a small proportion of patients still suffer from tumor recurrence or drug resistance. Molecular targeted drugs and dehypermethylation drugs have more promising outcomes in aggressive thyroid cancer compared with conventional treatments.
Based on what was discussed in this review, we suggest that integration of epigenetic and targeted therapies into conventional treatments will reduce the occurrence of refractory radioiodine differentiated thyroid cancer and improve the outcomes in aggressive thyroid cancer patients.
KeywordsDNA methylation BRAF mutation Thyroid cancer Personalized therapy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This manuscript is a review of the literature and does not contain original research either on animal or on human subjects.
For this type of study, informed consent is not required.
- 4.Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Hölzer S (2000) Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. US and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89(1):202–217CrossRefGoogle Scholar
- 21.Stephen JK, Chen KM, Merritt J et al (2015) Methylation markers for early detection and differentiation of follicular thyroid cancer subtypes. Cancer Clin Oncol 4(2):1–12Google Scholar
- 22.Schagdarsurengin U, Gimm O, Hoang Vu et al (2002) Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62(13):3698–3701Google Scholar
- 26.Adamczewski Z, Makarewicz J, Mikosiński S et al (2006) Application of 13-cis-retinoic acid in patients with 131I scintigraphically negative metastases of differentiated thyroid carcinoma. Endokrynol Pol 57(4):403–406Google Scholar
- 33.Xing M, Usadel H, Cohen Y et al (2003) Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 63(9):2316–2321Google Scholar
- 39.Kimura ET, Nikiforova MN, Zhu Z et al (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457Google Scholar